UNIGE document Scientific Article
previous document  unige:21327  next document
add to browser collection

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma

Stupp, Roger
Hegi, Monika E.
Neyns, Bart
Goldbrunner, Roland
Schlegel, Uwe
Clement, Paul M. J.
Grabenbauer, Gerhard G.
Ochsenbein, Adrian F.
show hidden authors show all authors [1 - 19]
Published in Journal of Clinical Oncology. 2010, vol. 28, no. 16, p. 2712-2718
Abstract PURPOSE: Invasion and migration are key processes of glioblastoma and are tightly linked to tumor recurrence. Integrin inhibition using cilengitide has shown synergy with chemotherapy and radiotherapy in vitro and promising activity in recurrent glioblastoma. This multicenter, phase I/IIa study investigated the efficacy and safety of cilengitide in combination with standard chemoradiotherapy in newly diagnosed glioblastoma. PATIENTS AND METHODS: Patients (age ≥ 18 to ≤ 70 years) were treated with cilengitide (500 mg) administered twice weekly intravenously in addition to standard radiotherapy with concomitant and adjuvant temozolomide. Treatment was continued until disease progression or for up to 35 weeks. The primary end point was progression-free survival (PFS) at 6 months. RESULTS: Fifty-two patients (median age, 57 years; 62% male) were included. Six- and 12-month PFS rates were 69% (95% CI, 54% to 80%) and 33% (95% CI, 21% to 46%). Median PFS was 8 months (95% CI, 6.0 to 10.7 months). Twelve- and 24-month overall survival (OS) rates were 68% (95% CI, 53% to 79%) and 35% (95% CI, 22% to 48%). Median OS was 16.1 months (95% CI, 13.1 to 23.2 months). PFS and OS were longer in patients with tumors with O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation (13.4 and 23.2 months) versus those without MGMT promoter methylation (3.4 and 13.1 months). The combination of cilengitide with temozolomide and radiotherapy was well tolerated, with no additional toxicity. No pharmacokinetic interactions between temozolomide and cilengitide were identified. CONCLUSION: Compared with historical controls, the addition of concomitant and adjuvant cilengitide to standard chemoradiotherapy demonstrated promising activity in patients with glioblastoma with MGMT promoter methylation.
Keywords AdultAgedAntineoplastic Agents, Alkylating/administration & dosage/adverse effectsBiopsy, NeedleBrain Neoplasms/*mortality/pathology/*therapyCombined Modality TherapyConfidence IntervalsDacarbazine/administration & dosage/adverse effects/*analogs & derivativesDisease-Free SurvivalDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesGlioblastoma/*mortality/pathology/*therapyHumansImmunohistochemistryInfusions, IntravenousKaplan-Meier EstimateMaleMaximum Tolerated DoseMiddle AgedNeoplasm Recurrence, Local/mortality/pathologyNeoplasm StagingNeurosurgical Procedures/methodsProbabilityRadiotherapy, AdjuvantRadiotherapy, ConformalRisk AssessmentSnake Venoms/*administration & dosage/adverse effectsSurvival AnalysisTreatment Outcome
PMID: 20439646
Full text
Article - document accessible for UNIGE members only Limited access to UNIGE
Other version: http://jco.ascopubs.org/content/28/16/2712.full.pdf
Research group Immunothérapie des cancers (42)
(ISO format)
STUPP, Roger et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. In: Journal of Clinical Oncology, 2010, vol. 28, n° 16, p. 2712-2718. https://archive-ouverte.unige.ch/unige:21327

195 hits

0 download


Deposited on : 2012-05-23

Export document
Format :
Citation style :